Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierCentre de Biologie Intégrative [CBI]
hal.structure.identifierCentre de Recherches sur la Cognition Animale - UMR5169 [CRCA]
dc.contributor.authorBULLICH, Sebastien
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorMARTIN, Hugo
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorFIORAMONTI, Xavier
hal.structure.identifierCentre de Biologie Intégrative [CBI]
hal.structure.identifierCentre de Recherches sur la Cognition Animale - UMR5169 [CRCA]
dc.contributor.authorGUIARD, Bruno P.
dc.date.accessioned2023-05-31T07:50:49Z
dc.date.available2023-05-31T07:50:49Z
dc.date.issued2022-12
dc.identifier.issn0007-9960en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182380
dc.description.abstractEnMajor depression (MD) is a psychiatric pathology based on different neurobiological mechanisms. Among these mechanisms, there is a hypersensitivity of the hypothalamic-pituitary-adrenal axis and modifications of various processes such as inflammation and oxidative stress. Various arguments suggest that these mechanisms lead to a deficit in monoaminergic neurotransmission. In particular, major depression is thought to result from an attenuation of serotonin (5-HT) levels in the brain. There is increasing evidence that patients with type 1 and type 2 diabetes are more likely to develop mood disorders than patients without diabetes. These epidemiological data are supported by studies conducted in different animal models displaying deficit in insulin signaling (exposure to cytotoxic compounds to the insulin-producing beta cell or hyperlipidic diets) leads to depressive-like states. This article summarizes the evidence linking metabolic and psychiatric disorders. It then presents the different mechanistic hypotheses that may explain this comorbidity. Finally, it opens the way to new therapeutic avenues that would consist in using oral antidiabetic drugs alone or in combination with antidepressants for an optimal management of MD. © 2022 Société française de nutrition
dc.language.isoENen_US
dc.subject.enDépression
dc.subject.enDiabète
dc.subject.enObésité
dc.subject.enInsuline
dc.subject.enMonoamines
dc.subject.enDepression
dc.subject.enDiabetes
dc.subject.enObesity
dc.subject.enInsulin
dc.subject.enMonoamines
dc.title.enHyperlipidic diets and depression [Régimes hyperlipidiques et dépression]
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.cnd.2022.07.001en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
bordeaux.journalCahiers de Nutrition et de Dietetiqueen_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04111452
hal.version1
hal.date.transferred2023-05-31T07:50:51Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cahiers%20de%20Nutrition%20et%20de%20Dietetique&rft.date=2022-12&rft.eissn=0007-9960&rft.issn=0007-9960&rft.au=BULLICH,%20Sebastien&MARTIN,%20Hugo&FIORAMONTI,%20Xavier&GUIARD,%20Bruno%20P.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée